BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma.
Carlos Chiattone(Hospital Samaritano de São Paulo), Fernando Augusto Soares(University of Connecticut)
Cited by 39
Related Papers
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
|British Journal of Cancer|2007|294
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
|Modern Pathology|2008|278
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
|Journal of Clinical Oncology|2011|256